Hookworm-Derived Ac-TMP-2 Protein for Inflammation Treatment

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for treating inflammation are limited in their broad-based efficacy, particularly in addressing various causes of inflammation such as asthma and inflammatory bowel disease.

Innovation Solution

The use of tissue metalloprotease inhibitor proteins derived from hookworms, specifically Ac-TMP-2 or its biologically active fragments or variants, in combination with pharmaceutically acceptable carriers and additional agents like NSAIDs or corticosteroids, to reduce, alleviate, or prevent inflammation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If conventional anti-inflammatory methods are used, then some inflammatory conditions are treated, but broad-based efficacy across various causes of inflammation is limited

Engineering Contradiction:
Improvebroad-based efficacyVSAvoidtreatment effectiveness
Core Design Contradiction:
Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies universality by using Ac-TMP-2, a tissue metalloprotease inhibitor derived from hookworms, which can effectively treat multiple types of inflammation caused by different mechanisms (asthma, inflammatory bowel disease, and other inflammatory conditions). This single agent provides broad-based efficacy across various inflammatory causes, resolving the contradiction between treatment versatility and reliability.

Inventive Principle:
Principle #6Universality (Multi-functionality)

2Reliability

If Ac-TMP-2 is used alone, then inflammation is reduced, but combination with additional agents provides enhanced therapeutic benefit

Engineering Contradiction:
Improvetherapeutic effectivenessVSAvoidcomposition complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies merging by combining Ac-TMP-2 with pharmaceutically acceptable carriers and additional therapeutic agents (such as NSAIDs, corticosteroids, or other anti-inflammatory drugs) to create composite pharmaceutical compositions. This combination approach enhances therapeutic effectiveness for treating inflammation while managing the complexity through standardized formulation practices.

Inventive Principle:
Principle #5Merging (Combining)

Data Source

PatentEP2849778B1Ac-TMP-2 FOR USE IN TREATING INFLAMMATION
Publication Date: 2017.12.27 JAMES COOK UNIVERSITY
  • EP2849778B1 patent drawingFigure 1~2
  • EP2849778B1 patent drawingFigure 3~4
  • EP2849778B1 patent drawingFigure 5~6

AI summary

A method for reducing or alleviating inflammation in a subject includes administering to the subject a therapeutically effective amount of : (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b), to thereby reduce or alleviate inflammation in the subject. A method for preventing or treating asthma or inflammatory bowel disease in a subject includes administering to the subject a therapeutically effective amount of: (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b), to thereby prevent or treat asthma or inflammatory bowel disease in the subject. The subject may be a mammal, inclusive of humans.